ALZN — Alzamend Neuro Cashflow Statement
0.000.00%
Last trade - 00:00- $8.44m
- $2.82m
Annual cashflow statement for Alzamend Neuro, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.05 | -12.4 | -14.9 | -9.95 | -4.51 |
| Depreciation | |||||
| Non-Cash Items | 2.49 | 4.42 | 3.58 | 0.956 | 0.334 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.152 | 1.33 | 2.35 | 0.671 | -2.44 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -2.71 | -6.61 | -8.92 | -8.27 | -6.57 |
| Capital Expenditures | — | -0.106 | 0 | -0.147 | -0.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.101 | 0 | — | — | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.101 | -0.106 | 0 | -0.147 | -0.3 |
| Financing Cash Flow Items | 1.95 | -0.059 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.45 | 18.9 | 0 | 3.65 | 10.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.84 | 12.1 | -8.92 | -4.76 | 3.57 |